Norris Perne & French LLP MI Sells 3,948 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Norris Perne & French LLP MI trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,054 shares of the medical research company’s stock after selling 3,948 shares during the quarter. Charles River Laboratories International comprises about 1.7% of Norris Perne & French LLP MI’s portfolio, making the stock its 23rd biggest position. Norris Perne & French LLP MI owned approximately 0.25% of Charles River Laboratories International worth $23,270,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Forsta AP Fonden boosted its holdings in Charles River Laboratories International by 6.6% during the 4th quarter. Forsta AP Fonden now owns 11,300 shares of the medical research company’s stock worth $2,086,000 after acquiring an additional 700 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Charles River Laboratories International by 3.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company’s stock worth $804,000 after buying an additional 126 shares in the last quarter. KBC Group NV increased its holdings in Charles River Laboratories International by 0.9% during the 4th quarter. KBC Group NV now owns 85,362 shares of the medical research company’s stock worth $15,758,000 after acquiring an additional 796 shares during the period. Blue Trust Inc. increased its holdings in shares of Charles River Laboratories International by 7.8% in the fourth quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company’s stock worth $398,000 after purchasing an additional 146 shares during the period. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $237,000. 98.91% of the stock is currently owned by institutional investors.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

CRL stock opened at $165.38 on Friday. The business has a 50-day moving average price of $184.77 and a 200 day moving average price of $196.03. Charles River Laboratories International, Inc. has a 1-year low of $159.65 and a 1-year high of $275.00. The company has a market capitalization of $8.46 billion, a P/E ratio of 20.70, a PEG ratio of 6.13 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $2.72 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of several analyst reports. UBS Group restated a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $204.38.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).